We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genalyte Launches Early Access Program for Maverick™ Next-Generation Multiplexing Platform
Product News

Genalyte Launches Early Access Program for Maverick™ Next-Generation Multiplexing Platform

Genalyte Launches Early Access Program for Maverick™ Next-Generation Multiplexing Platform
Product News

Genalyte Launches Early Access Program for Maverick™ Next-Generation Multiplexing Platform


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Genalyte Launches Early Access Program for Maverick™ Next-Generation Multiplexing Platform"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genalyte, Inc. has announced that it will launch an Early Access program for its Maverick™ Detection System and multiplexed autoimmune assays at two major immunology meetings in May.

Genalyte will host booths and present scientific data on the performance of the Maverick platform at Immunology 2012™, the 99th Meeting of the American Association of Immunologists, and at the 8th International Congress on Autoimmunity.

Genalyte’s Early Access program enables scientists to gain pre-launch access to multiplexed autoantibody assays and the Maverick platform, which uses a patented silicon chip containing arrays of photonic microring sensors that can simultaneously analyze multiple proteins from a single small sample.

“These meetings will allow us to introduce the unique capabilities of the Maverick platform and our Early Access program to prominent immunology researchers,” said Genalyte CEO Cary Gunn.

Gunn continued, "Feedback from our Early Access customers should be very helpful as we prepare for full commercialization of the Maverick platform in the coming months.”

Maverick Detection System assays do not require the washes, incubations, reagents or other processing steps typically needed for sample preparation. They are simple to use and rapid - results are available in only 15 minutes, including just two minutes of hands-on time.

The Maverick platform has a large dynamic range and excellent sensitivity, with good reproducibility and no cross talk.

At Immunology 2012™, Dr. Gunn will host a workshop discussing Genalyte’s Maverick Detection System on May 7, 2012 from 10:00-11:00am in Room 203. Information on the Maverick Detection System will be available at Genalyte’s Booth 103.

At the 8th International Congress on Autoimmunity, Genalyte will present at Poster Session 1 on May 10, 2012 from 10:00am-5:00pm, Poster 1731. Information on the Maverick Detection System will be available at Genalyte’s Booth 17A.

Immunology 2012 will be held in Boston, MA, May 4-8, 2012. For more information, visit http://immunology2012.org.

The 8th International Congress on Autoimmunity will be held in Granada, Spain, May 9-13, 2012. For more information, visit http://www2.kenes.com/autoimmunity/pages/home.aspx.

Advertisement